Apple Pharmaceuticals

We are manfacturer,trader & supplier of  Velpanat tablet. Velpanat is the fixed dose combination of these two most widely used anti-viral agents. Sofosbuvir & Velpatasvir are directly acting anti-viral agents which are involved in the treatment of chronic hepatitis C viral infection. Sofosbuvir is usually combined with other anti-viral agent for exhibiting the prominent effects. Velpanat is the FDA approved product, which is used in chronic HCV condition. Velpanat should be used in genotype I, II, III, IV, V or VI associated hepatitis C viral infections.

DOSAGE BEFORE THE TREATMENT

Examine the patients thoroughly, before initiating the treatment with HCV anti-viral agents. Care should be taken while using HCV medication in patients with HCV/HIV-1co infections, in this case HBV reactivation occurs. Velpanat tablets are recommended for chronic condition of hepatitis C viral infection related to genotype 1, 2, 3, 4, 5 or 6. The dosing of Velpanat; The usual recommended dose of Velpanat is, one tablet should be administered orally as a single dose. Velpanat tablet consist of 100mg of Velpatasvir & 400mg of Sofosbuvir

WORKS

 

Sofosbuvir is a NS5B protein inhibitor, protein is essential for viral production. Sofosbuvir is a prodrug form, which get converted into active uridine triphosphate form which is required for anti-viral activity. This dynamic active moiety is get inserted into HCV RNA with the help of NS5B polymerase and leads as chain eliminator. Velpatasvir is pharmacologically acts as NS5A inhibitor; this protein is required for HCV viral production. Velpatasvir is involved its action in viral production process.
UNFAVORABLE EFFECTS 

Serious bradycardia occurs due to concomitant use of Velpanat with amiodarone. Insomnia Irritability Headache Fatigue Nausea Asthenia

LAB ABNORMALITIES

Lipase elevation Elevation of creatine kinase Elevation of bilirubin levels

POST MARKETING EFFECTS

Cardiac disorders Rashes Angioedema

Velpanat Tablet Manufactured & Marketed By Natco Pharma Ltd

Additional Information:

• Production Capacity: Large
• Delivery Time: Immediate
• Packaging Details: 1x28 Tablets in a bottle

We are manfacturer,trader & supplier of  Myhep-All tablets.

Myhep-All is the fixed dose combination of these two most widely used anti-viral agents. Sofosbuvir & Velpatasvir are directly acting anti-viral agents which are involved in the treatment of chronic hepatitis C viral infection. Sofosbuvir is usually combined with other anti-viral agent for exhibiting the prominent effects. Myhep-All is the FDA approved product, which is used in chronic HCV condition. Myhep-All should be used in genotype I, II, III, IV, V or VI associated hepatitis C viral infections.

 

 

DOSAGE BEFORE THE TREATMENT

Examine the patients thoroughly, before initiating the treatment with HCV anti-viral agents. Care should be taken while using HCV medication in patients with HCV/HIV-1co infections, in this case HBV reactivation occurs. Myhep-All tablets are recommended for chronic condition of hepatitis C viral infection related to genotype 1, 2, 3, 4, 5 or 6. The dosing of Myhep-All; The usual recommended dose of Myhep-All is, one tablet should be administered orally as a single dose. Myhep-All tablet consist of 100mg of Velpatasvir & 400mg of Sofosbuvir

 

mechanism of actions

Sofosbuvir is a NS5B protein inhibitor, protein is essential for viral production. Sofosbuvir is a prodrug form, which get converted into active uridine triphosphate form which is required for anti-viral activity. This dynamic active moiety is get inserted into HCV RNA with the help of NS5B polymerase and leads as chain eliminator. Velpatasvir is pharmacologically acts as NS5A inhibitor; this protein is required for HCV viral production. Velpatasvir is involved its action in viral production process

 

Dosage and Administration

 

Patients suffered with compensated cirrhosis or without cirrhosis; One tablet of Myhep-All should be administered orally as once daily over period of 12 weeks. Patients suffered with decompensated cirrhosis; One Myhep-All tablet should be combined with weight based ribavirin by administering with food for 12 hours. The dose of ribavirin should be calculated for the patients; Patient with <75kg of body weight, the recommended dose of ribavirin is 1000mg administered as twice daily. Patient with at least 75kg of body weight, recommended dose of ribavirin is 1200mg administered as twice daily. For both renal & hepatic impaired patients; Myhep-All tablets dosage adjustment should not be recommended.

PHARMACOKINETICS

The maximum plasma concentration of Myhep-All is;
Sofosbuvir at 0.5 to 1 hour & Velpatasvir at 3 hours Food does not affect the absorption of Myhep-All The Myhep-All tablet is highly bound to human plasma protein is; Sofosbuvir 61 to 65% & Velpatasvir by >99.5%
The blood plasma ratio of;
Sofosbuvir 0.7 & Velpatasvir 0.52 to 0.67. The Myhep-All metabolism is majorly occurs in liver; sofosbuvir by cathepsin A or carboxyl esterase 1 & Velpatasvir by CYP2B6, CYP2C8 or CYP3A4.
Myhep-All excretion occurs via;
Sofosbuvir by urine (80%), feces (14%) & exhaled air (2.5%) & Velpatasvir by urine (88%) & feces (6.6%) The half lives of Myhep-All;
UNFAVORABLE EFFECTS 

Serious bradycardia occurs due to concomitant use of Myhep All with amiodarone. Insomnia Irritability Headache Fatigue Nausea Asthenia

LAB ABNORMALITIES

Lipase elevation Elevation of creatine kinase Elevation of bilirubin levels

POST MARKETING EFFECTS

Myhep all is manufactured and marketed by Mylan ltd

 

Additional Information:

• Production Capacity: large
• Packaging Details: 1 x 28 tabs in a bottle

We are manfacturer,trader & supplier of Hepcvel Tablets. Hepcvel is Sofosbuvir 400mg & Velpatasvir 100mg is the fixed dose combination of these two most widely used anti-viral agents. Sofosbuvir & Velpatasvir are directly acting anti-viral agents which are involved in the treatment of chronic hepatitis C viral infection. Sofosbuvir is usually combined with other anti-viral agent for exhibiting the prominent effects. Hepcvel is the FDA approved product, which is used in chronic HCV condition. Hepcvel should be used in genotype I, II, III, IV, V or VI associated hepatitis C viral infections.
DOSAGE BEFORE THE TREATMENT

Examine the patients thoroughly, before initiating the treatment with HCV anti-viral agents. Care should be taken while using HCV medication in patients with HCV/HIV-1co infections, in this case HBV reactivation occurs. Hepcvel tablets are recommended for chronic condition of hepatitis C viral infection related to genotype 1, 2, 3, 4, 5 or 6. The dosing of Hepcvel; The usual recommended dose of Hepcvel is, one tablet should be administered orally as a single dose. Hepcvel tablet consist of 100mg of Velpatasvir & 400mg of Sofosbuvir
UNFAVORABLE EFFECTS

Serious bradycardia occurs due to concomitant use of Hepcvel with amiodarone. Insomnia Irritability Headache Fatigue Nausea Asthenia

Additional Information:

• Production Capacity: Large
• Delivery Time: Immediate
• Packaging Details: 28 Tablets in a Bottle

We are manufacturer,trader & supplier of Velasof Tablets.
Velasof Tablets  contains Sofosbuvir 400mg and Velpatasvir 100mg used to treat HCV infections ( Hepatitis C)

How Velasof Tablet works

Velasof Tablet is a combination of two antiviral medicines: Sofosbuvir and Velpatasvir. They work by lowering the amount of hepatitis C virus in the body and removing the virus from the blood over a period of time.

How to use Velasof Tablet

 Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Velasof Tablet may be taken with or without food, but it is better to take it at a fixed time.

Velasof is manufactured and marketed by Hetero Healthcare Ltd

Additional Information:

• Production Capacity: Large
• Delivery Time: Immediate
• Packaging Details: 1 x 28 tabs in a bottle

We are manfacturer,trader & supplier of    Resof Total.
Resof Total is a two-drug combination for the treatment of hepatitis C. It is administered as a single daily pill containing the viral NS5A inhibitor velpatasvir and sofosbuvir,a nucleotide inhibitor of the viral RNA polymerase. It is the first treatment, that works for all genotypic, and is taken entirely by mouth. A single tablet regimen is used for adults with genotype 1-6 chronic hepatitis C virus (HCV) infection with pangenotypic activity.

Additional Information:

• Production Capacity: Large
• Delivery Time: Immediate
• Packaging Details: 28 Tablets in a bottle